Start the conversation
Or to contact Money Morning Customer Service, click here.
Biotechnology is tech's fastest-growing sector. In fact, there are more than 100 biotech companies set to go public in 2015.
Of those 100 IPOs, 60 are expected to launch before April 1. So you have to move fast to ride this $320 billion biotech wave.
Those IPOs are all but certain to keep the biotech bull market going through the year. Biotech stocks have soared 290% in the past five years. That's more than triple the S&P's 88%.
And biotech IPOs are not the only catalysts that will lift biotech shares across the board in 2015.
One reason is the sheer number of new "blockbuster" drugs expected to reach market. By this time next year, the FDA is expected to approve as many as 11 new treatments.
The big question is: How will you profit?
How to Profit from Biotech Companies in 2015
I've found one biopharmaceutical company that's projected to have $10.5 billion in yearly sales. Not to mention its leading drug is set to grow an incredible 50% over the next 24 months.
The company just negotiated a major deal with a "deep pockets" partner to develop an Alzheimer's treatment. This new drug could be an incredible opportunity for both investors and the Alzheimer's market.
But even those catalysts for success pale in comparison to this one…
Thanks to its breakthrough treatment for chronic hepatitis C, the biotech company I'm talking about is close to gaining control of a $13 billion market.
This firm's new treatment is so promising that the federal government has placed it on the rare "fast track" to approval. The largest U.S. pharmacy benefits manager publicly said it will likely adopt the treatment for its millions of hepatitis C patients. The company is currently finishing up clinical trials and could be approved any day.
When that day finally comes, I expect to see the company's stock price to boom.
I think we're looking at easy triple digits. And the company's hefty annual dividend of nearly 3% makes the deal even sweeter.
This biotech stock is only one of seven potentially high-profit moves I've tracked down. They can all quadruple your money and give you 8.2% in annual dividends.
All of the details are in my 2015 Tech Investor's Forecast, which I'd like to send you now…
You see, all the ingredients are now present for a multiyear run in tech stocks that will dwarf anything we've seen before – creating a slew of new tech millionaires. Make the right moves and you can be one of them. I will show you exactly what to do with this 2015 Tech Investor's Forecast . It highlights seven specific tech stocks to buy right now that could create Alibaba-like wealth this year.
About the Author
Michael A. Robinson is one of the top financial analysts working today. His book "Overdrawn: The Bailout of American Savings" was a prescient look at the anatomy of the nation's S&L crisis, long before the word "bailout" became part of our daily lexicon. He's a Pulitzer Prize-nominated writer and reporter, lauded by the Columbia Journalism Review for his aggressive style. His 30-year track record as a leading tech analyst has garnered him rave reviews, too. Today he is the editor of the monthly tech investing newsletter Nova-X Report as well as Radical Technology Profits, where he covers truly radical technologies – ones that have the power to sweep across the globe and change the very fabric of our lives – and profit opportunities they give rise to. He also explores "what's next" in the tech investing world at Strategic Tech Investor.
Tags: biotech companies, biotech companies 2015, biotech IPOs, biotech shares, biotech stocks, biotech stocks 2015, how to invest in biotech, how to invest in biotech companies, how to profit from biotech, how to profit from biotech companies, new biotech companies